Testing telitacicept vs cyclophosphamide for lupus lung disease
Treatments studied
Part of Immune system & allergy, Lungs & breathing, Skin clinical trials.
This trial tests if a new drug called telitacicept works better than a standard lupus medicine (cyclophosphamide) to improve lupus-related lung scarring (interstitial lung disease). It might be an option if your breathing tests are still good enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with lupus.
- You must have a lung condition called interstitial lung disease, confirmed by a CT scan.
- Your breathing test results must show at least 60% of normal lung function for FEV1/FVC, and a diffusion capacity of 40% or higher.
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the trial.
- You cannot have severe liver, kidney, or blood problems, a history of bleeding risks, or be on strong blood thinners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called Telitacicept to see if it can prevent lupus flares in people whose disease is currently mild or stable. It may be a good option if you want to keep your lupus under control and avoid sudden worsening.
This clinical trial tests a new drug called telitacicept for people who have both Sjögren's syndrome and interstitial lung disease. The drug aims to reduce the immune system's attack on your body and may help improve lung symptoms.
This trial compares two medications, telitacicept and belimumab, to see which is safer and more effective for treating lupus. It might help you if standard treatments haven't worked well for you.
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests a new treatment called CT1192, which uses your own immune cells (T-cells) that are modified to target and calm overactive immune cells causing lupus. It is designed for people with moderate to severe lupus that hasn't improved with standard therapies like steroids, immunosuppressants, or biologics.
Hear when a new Lupus or SLE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.